Story

BPER Banca Downgraded to Hold by Kepler Cheuvreux on Merger Delay Concerns

ENTHMSVIIDZHZH-TWJAKOHI
Jul 14, 20261 min read
BPER Banca Downgraded to Hold by Kepler Cheuvreux on Merger Delay Concerns

Summary

Kepler Cheuvreux lowered its rating on BPER Banca to Hold from Buy, citing expectations that a potential merger with Banca Monte dei Paschi di Siena is unlikely to occur until late 2027.

Text size
Background

Kepler Cheuvreux has lowered its rating on BPER Banca (EMII:BPER) to Hold from a previous Buy rating, pointing to concerns about the timeline for a potential merger with rival Italian bank Banca Monte dei Paschi di Siena. The brokerage's note on Tuesday highlighted the uncertainty of a deal materializing in the near term amid rapidly changing market conditions.

Merger Timing at Core of Downgrade

The primary driver for the ratings change is the revised expectation for a combination with Banca Monte dei Paschi di Siena (EMII:BMPS). According to Kepler Cheuvreux, such a transaction is now not anticipated to occur until late 2027.

While the brokerage described a possible deal with Monte dei Paschi as a "great opportunity" for BPER Banca, the extended timeline reduces its appeal as a short-term catalyst for investors.

Near-Term Outlook

Sample IUX Markets – In-articleAd

Kepler Cheuvreux also commented on other factors influencing its view. The firm stated it does not see the upcoming update of BPER’s business plan for integrating Banca Popolare di Sondrio as a significant catalyst for the stock.

On a positive note, the brokerage acknowledged that BPER Banca's upcoming second-quarter results are expected to benefit significantly from a one-time financial gain.

Market Reaction

Following the rating change, shares of BPER Banca fell 1.8% during Tuesday's trading session. The downgrade introduces a more cautious stance from the brokerage on the bank's near-term prospects, shifting the focus from potential M&A activity to its standalone operational performance.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST